Madeline Anne Dorso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Madeline Anne Dorso has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Deborah A. Gordon
17 shared publications- Ian C.A. Taylor
Arvinas Operations, Inc 5 Science Park 395 Winchester Ave 06511 New Haven CT United States
17 shared publications - Jennifer Pizzano
Arvinas Operations, Inc 5 Science Park 395 Winchester Ave 06511 New Haven CT United States
17 shared publications - John G. Houston
Arvinas Operations, Inc 5 Science Park 395 Winchester Ave 06511 New Haven CT United States
17 shared publications - Kaitlynn Robling
Department of Biology, Arvinas Operations, Inc., New Haven, Connecticut
17 shared publications - Lawrence B. Snyder
Department of Chemistry, Arvinas Operations, Inc., New Haven, Connecticut
17 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S4 shows maintenance of animal body weights during treatment with bavdegalutamide or enzalutamide in prostate cancer mouse models
- 22 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S4 shows maintenance of animal body weights during treatment with bavdegalutamide or enzalutamide in prostate cancer mouse models
- Open Access
- 22 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S2 shows the effect of bavdegalutamide on neomorphic substrates
- 22 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S2 shows the effect of bavdegalutamide on neomorphic substrates
- Open Access
- 22 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S1 shows the effect of bavdegalutamide on AR versus AR-V7
- 22 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S1 shows the effect of bavdegalutamide on AR versus AR-V7
- Open Access
- 22 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Table S1 shows bavdegalutamide half-maximal degradation concentrations for wild-type and clinically relevant mutant AR
- 22 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Table S1 shows bavdegalutamide half-maximal degradation concentrations for wild-type and clinically relevant mutant AR
- Open Access
- 22 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S3 shows the effect of bavdegalutamide on SALL4
- 22 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S3 shows the effect of bavdegalutamide on SALL4
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S1 shows the effect of bavdegalutamide on AR versus AR-V7
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S1 shows the effect of bavdegalutamide on AR versus AR-V7
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S3 shows the effect of bavdegalutamide on SALL4
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S3 shows the effect of bavdegalutamide on SALL4
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Table S1 shows bavdegalutamide half-maximal degradation concentrations for wild-type and clinically relevant mutant AR
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Table S1 shows bavdegalutamide half-maximal degradation concentrations for wild-type and clinically relevant mutant AR
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S2 shows the effect of bavdegalutamide on neomorphic substrates
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S2 shows the effect of bavdegalutamide on neomorphic substrates
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S4 shows maintenance of animal body weights during treatment with bavdegalutamide or enzalutamide in prostate cancer mouse models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader
Supplementary Figure S4 shows maintenance of animal body weights during treatment with bavdegalutamide or enzalutamide in prostate cancer mouse models